News

Nivalis president and CEO Jon Congleton said: "The Orphan Drug Designation represents an important milestone in the development and regulatory strategy for N91115 and underscores the unmet need

HMPL-523 is a novel, highly selective and potent small molecule oral inhibitor targeting spleen tyrosine kinase, also known as Syk, a key component in B-cell receptor signalling. Preparations

Bial said it is working with health authorities to understand the causes of this tragic and unfortunate situation. The yet to be named drug, believed to be BIA

The approval follows a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use. In a phase 3 clinical trial, Benepali showed comparable safety

The drug has now been approved to treat adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA) inflammatory diseases, which affect the joints and/or spine. The

Isomerase discovers and develops molecules that target peptidyl-prolyl isomerases including cyclophilins. The acquisition intends to further improve the collaboration between the firms and speed up NeuroVive’s research and

Selinexor is the company’s oral selective inhibitor of Nuclear Export (SINE) compound. It binds to and inhibits the nuclear export protein XPO1, resulting in the accumulation of tumor

Imetelstat, discovered by Geron, is a potent and specific inhibitor of telomerase that is administered by intravenous infusion. The clinical trial, also referred to as the IMerge study,

TheraKine has developed sustained release delivery technology platforms for injectable local delivery of biologic agents and live cells. Cell Care uses stem cells to treat degenerative and inflammatory